Boston Scientific’s (BSX) “Hold” Rating Reaffirmed at Argus

Argus reiterated their hold rating on shares of Boston Scientific (NYSE:BSX) in a report published on Friday, MarketBeat reports.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday. Mizuho reduced their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Finally, Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

NYSE:BSX opened at $46.75 on Friday. The stock has a 50 day moving average of $46.13 and a two-hundred day moving average of $62.26. Boston Scientific has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a market cap of $69.48 billion, a P/E ratio of 18.93, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 9,800 shares of company stock valued at $554,012 in the last three months. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of BSX. Cary Street Partners Financial LLC grew its stake in shares of Boston Scientific by 16.7% in the 2nd quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock valued at $1,071,000 after buying an additional 3,597 shares during the period. Farther Finance Advisors LLC raised its position in shares of Boston Scientific by 28.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock valued at $1,227,000 after buying an additional 6,427 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in Boston Scientific by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock valued at $2,106,000 after acquiring an additional 1,119 shares during the last quarter. Simplify Asset Management Inc. lifted its holdings in Boston Scientific by 32.6% in the second quarter. Simplify Asset Management Inc. now owns 15,014 shares of the medical equipment provider’s stock valued at $641,000 after acquiring an additional 3,690 shares during the last quarter. Finally, Riversedge Advisors LLC purchased a new position in Boston Scientific in the second quarter worth approximately $320,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.